Key Points
- Director John William Wulf bought 81,000 AGL shares on Nov. 12 at an average price of $0.63 (about $51,030), increasing his stake ~28.4% to 365,857 shares—an insider purchase often read as a sign of confidence.
- Agilon reported Q results showing an EPS miss—($0.27) vs. consensus ($0.18)—with revenue roughly in line at $1.44 billion; the stock recently traded around $0.84 (down 3.1%), with a $346 million market cap and a 12‑month range of $0.51–$6.08.
- Brokerage coverage is mixed with an average rating of “Hold” and a $2.71 average price target, while multiple law firms have filed suits or opened investigations, creating notable legal/headline risk for the company.
Agilon Health, Inc. (NYSE:AGL - Get Free Report) Director John William Wulf bought 81,000 shares of the company's stock in a transaction dated Wednesday, November 12th. The stock was bought at an average price of $0.63 per share, for a total transaction of $51,030.00. Following the transaction, the director owned 365,857 shares of the company's stock, valued at approximately $230,489.91. This trade represents a 28.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Agilon Health Stock Down 3.1%
AGL opened at $0.84 on Friday. The company has a 50-day moving average price of $0.78 and a 200 day moving average price of $1.03. The company has a market cap of $346.22 million, a PE ratio of -1.11 and a beta of 0.05. Agilon Health, Inc. has a twelve month low of $0.51 and a twelve month high of $6.08.
Agilon Health (NYSE:AGL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09). The business had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.43 billion. Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%. As a group, sell-side analysts expect that Agilon Health, Inc. will post -0.59 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms have recently commented on AGL. Barclays reduced their price target on shares of Agilon Health from $1.50 to $1.00 and set an "underweight" rating on the stock in a research report on Thursday, November 6th. Zacks Research raised Agilon Health from a "strong sell" rating to a "hold" rating in a research report on Tuesday, October 21st. Wells Fargo & Company cut their price objective on Agilon Health from $1.50 to $1.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 5th. Royal Bank Of Canada upgraded Agilon Health from a "hold" rating to a "moderate buy" rating in a report on Wednesday, December 3rd. Finally, BTIG Research restated a "neutral" rating on shares of Agilon Health in a research note on Friday, December 12th. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $2.71.
Read Our Latest Research Report on Agilon Health
Institutional Trading of Agilon Health
Institutional investors have recently modified their holdings of the stock. CenterBook Partners LP boosted its holdings in shares of Agilon Health by 492.4% in the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company's stock valued at $11,771,000 after buying an additional 9,499,012 shares in the last quarter. Voleon Capital Management LP raised its stake in Agilon Health by 5,519.2% during the 3rd quarter. Voleon Capital Management LP now owns 2,741,039 shares of the company's stock worth $2,823,000 after acquiring an additional 2,692,259 shares in the last quarter. UBS Group AG lifted its position in Agilon Health by 250.7% in the fourth quarter. UBS Group AG now owns 3,395,366 shares of the company's stock valued at $2,339,000 after acquiring an additional 2,427,136 shares during the last quarter. Millennium Management LLC lifted its position in Agilon Health by 280.4% in the third quarter. Millennium Management LLC now owns 2,998,838 shares of the company's stock valued at $3,089,000 after acquiring an additional 2,210,568 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Agilon Health by 41.3% in the third quarter. Bank of America Corp DE now owns 5,414,614 shares of the company's stock valued at $5,577,000 after acquiring an additional 1,581,284 shares in the last quarter.
More Agilon Health News
Here are the key news stories impacting Agilon Health this week:
- Positive Sentiment: Agilon director John William Wulf bought 81,000 AGL shares (avg. $0.63) in November, increasing his stake by ~28%—an insider purchase investors often view as a sign of confidence. Insider Form 4
- Neutral Sentiment: Brokerage consensus remains lukewarm: recent coverage shows an average recommendation of “Hold,” suggesting analysts are cautious but not uniformly bearish. Analyst Consensus
- Negative Sentiment: Bronstein, Gewirtz & Grossman filed/urged investors to act in a class action alleging investor harm against Agilon and certain officers—adds to legal exposure and headline risk. Bronstein, Gewirtz & Grossman filing
- Negative Sentiment: Faruqi & Faruqi says it is investigating claims on behalf of Agilon investors and is soliciting potential class members—more counsel activity increases likelihood of consolidated litigation and potential discovery/settlement costs. Faruqi & Faruqi notice
- Negative Sentiment: Multiple other plaintiff firms (Rosen, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, The Gross Law Firm) have filed or issued shareholder alerts reminding investors of lead‑plaintiff deadlines—this sustained outreach keeps Agilon in the legal headlines and may pressure the stock. Rosen Law Firm notice Levi & Korsinsky notice Bernstein Liebhard notice Pomerantz notice The Gross Law Firm notice
About Agilon Health
(
Get Free Report)
Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.
Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
